미국 · 보도자료 · GKOS · 2026-10-09 11:00
백내장 수술 병용 iDose TR 임상 4상 긍정적 톱라인 결과 발표
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunctio
